Join the Oncology Voice Network. Join for Free
The Industry Cuts Programs Too Early. And Learns Too Little.

The Industry Cuts Programs Too Early. And Learns Too Little.


Share This Article


Summary

The industry calls it a recruitment problem.

• Why "patient centricity" without patient inclusion is a label, not a strategy

• What the design decisions driving dropout actually look like

• The one question that changes the design before it locks

One Idea Worth Acting On.

A patient with stage-four lung cancer drives three hours to a clinical trial site.

The visit is for a five-minute blood draw.

He drops out the same day.

The industry calls it a recruitment problem.

The patient calls it impossible.

We call it a recruitment problem. But the real failure happened months earlier --- in the design room.

Patient centricity has become oncology's most repeated commitment --- and its most unexamined one. Organizations build advisory boards, add PRO instruments, and use "patient-centered' in every strategy deck.

But if patients are not in the room when the design decisions are made, that is not patient centricity. It is a label.

As Terri Conneran, patient advocate and contributor to Voices of Oncology, puts it: being the subject of the conversation is not the same as having a seat at the table. One means you are the dinner. The other means you helped plan the meal.

What's Actually Happening

Protocols are still being designed by teams whose calendars have nothing in common with someone managing stage-four cancer, a three-hour commute, and two children at home.

Visit schedules get reviewed for regulatory risk. Nobody reviews them for human feasibility.

When patient input is collected at all, it arrives late --- a PRO instrument added after the protocol locks, a survey distributed after enrollment begins. That is commentary. Not influence.

Why This Matters

Enrollment failure is the single most common reason oncology trials don\'t complete on time. Protocol burden --- excessive visits, impractical monitoring requirements, the financial toll of travel --- is one of the primary drivers.

This is not a motivation problem. Cancer patients are fighting for their lives. If they are dropping out, the protocol failed them --- not the other way around.

Designing without patients produces trials that generate data about an idealized population that does not exist in the clinic. That gap is one of the most persistent reasons approved drugs underperform post-launch.

Where It Breaks in the Real World

Elizabeth Franklin, Head of US Public Affairs and Patient Advocacy at Sanofi and contributor to Voices of Oncology, describes a patient with stage-four lung cancer who drove three hours to a clinical trial site --- only to discover the visit was for a blood draw. He dropped out the same day.

That schedule was reviewed by clinical, regulatory, IRB, and operational teams. Nobody asked the patient whether it was survivable.

The question was never asked because the patient was not in the room.

What Needs to Change

Patient inclusion at the design stage is not a virtue. It is the mechanism that prevents the enrollment failures and protocol amendments that cost the industry billions.

It means a patient present at protocol design --- not consulted afterward. A visit schedule tested against the reality of serious illness before it locks. An eligibility criterion challenged by someone who knows what the real patient population actually looks like.

The organizations getting this right are not doing more work. They are doing earlier work.

The Bottom Line

Until patients have standing to challenge design decisions before they lock, the industry will keep building trials for patients who don't exist --- and managing the dropout of the patients who do.

Add Your Voice --- Where are you seeing this? What\'s working --- and what's not?

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN